PMID: 15217206Jun 26, 2004Paper

Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice

Cancer Treatment and Research
Martin S Tallman

Abstract

Many new insights into the diagnosis, pathogenesis, clinical manifestation, treatment and prognosis of patients with AML reflect the heterogeneity of the disease. The initial descriptions of the various subtypes of AML, established by the FAB classification, were based on morphology and cytochemical stains. Although morphology remains the foundation for the diagnosis, additional diagnostic studies including immunophenotyping, cytogenetic evaluation, and molecular genetic studies have become critical, and in some specific cases, mandatory, complementary tools. Several specific subtypes of AML are now treated with directed or targeted therapy. Acute promyelocytic leukemia is currently the only example of a subtype of AML to which specific therapy targeted to a molecular genetic abnormality is available and this subtype now is highly curable. Future studies will address newly identified prognostic factors and gene mutations such as FLT3, Wilm's tumor (WTI), and CEBPA which will enable the further pathologic classification of patients with AML. Finally, microarray analysis will likely identify genes critically involved in the pathogenesis of specific pathologic subtypes.

Citations

May 10, 2005·Blood·Torsten HaferlachClaudia Schoch
Mar 17, 2007·The American Journal of Bioethics : AJOB·Joseph J Fins
Oct 3, 2012·Cytometry. Part B, Clinical Cytometry·Hanna DobrowolskaAdriana I Colovai
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jan BraessWolfgang Hiddemann
Mar 27, 2007·Advances in Enzyme Regulation·James A McCubreyAlberto M Martelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Best Practice & Research. Clinical Haematology
Martin S Tallman
Best Practice & Research. Clinical Haematology
Richard M Stone
Journal of Ayub Medical College, Abbottabad : JAMC
Mahadev S HaraniMohammmad Khurshid
Gan to kagaku ryoho. Cancer & chemotherapy
Shigeki Ohtake
© 2022 Meta ULC. All rights reserved